Investment Thesis
Zoetis demonstrates exceptional profitability with a 28.2% net margin and strong cash generation (2.3B FCF), positioning it as a high-quality business despite modest revenue growth of 2.3% YoY. The company maintains solid financial health with a 3.03x current ratio and 15.1x interest coverage, though elevated leverage (2.71x debt/equity) and flat net income growth warrant monitoring.
ZTS Strengths
- Industry-leading net margin of 28.2% and operating margin of 35.5% demonstrate exceptional operational efficiency
- Strong return metrics (80.2% ROE, 17.3% ROA) indicate superior capital deployment and asset utilization
- Robust free cash flow generation of 2.3B with 24.1% FCF margin supports sustainability and shareholder returns
- Healthy liquidity position (3.03x current ratio, 1.94x quick ratio) provides flexibility for operations and investments
ZTS Risks
- Muted revenue growth of 2.3% YoY raises concerns about top-line expansion and market share dynamics in competitive pharma sector
- Elevated debt burden of 9.0B creates leverage of 2.71x debt/equity, limiting financial flexibility and increasing refinancing risks
- Flat net income growth despite positive EPS growth suggests earnings per share gains driven primarily by share buybacks rather than operational improvements
- Modest 60 Form 4 filings in last 90 days may indicate limited insider confidence, though this warrants contextual analysis
Key Metrics to Watch
- Revenue growth trajectory and segment performance to confirm whether 2.3% growth represents a sustainable baseline or declining trend
- Net income growth and operating leverage to determine if profitability gains can accelerate beyond earnings per share buyback effects
- Debt reduction progress and debt/equity ratio trend to assess deleveraging strategy and financial risk mitigation
- Free cash flow stability and capital allocation priorities (dividends, buybacks, debt repayment, R&D investment)
ZTS Financial Metrics
Revenue
$9.5B
Net Income
$2.7B
EPS (Diluted)
$6.02
Free Cash Flow
$2.3B
Total Assets
$15.5B
Cash Position
$2.3B
ZTS Profitability Ratios
Gross Margin
N/A
Operating Margin
35.5%
Net Margin
28.2%
ROE
80.2%
ROA
17.3%
FCF Margin
24.1%
ZTS Balance Sheet & Liquidity
Current Ratio
3.03x
Quick Ratio
1.94x
Debt/Equity
2.71x
Debt/Assets
78.5%
Interest Coverage
15.14x
Long-term Debt
$9.0B
Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: Mar 18, 2026 |
Data as of: 2025-12-31 |
Powered by Claude AI